How plague pathogens trick the immune system

Yersinia pathogens inject the enzyme YopO into the macrophages of the immune system, preventing the defense cells from digesting the plague bacteria. This article outlines a study done on the ability of YopO to change its shape and confuse the immune system, allowing for a more targeted approach to treatment and possible eradication of Yersinia.

Safety and Clinical Outcomes of an Equine-Derived Heptavalent Botulinum Antitoxin Treatment for Confirmed or Suspected Botulism in the United States

 Treatment with BAT® [Botulism Antitoxin Heptavalent (Equine)] was associated with shorter hospital and intensive care unit stays.

Emergent BioSolutions awarded contract from HHS to support smallpox preparedness

The US Department of Health and Human Services (HHS) awarded a contract for $535 to Emergent BioSolutions Inc. for Vaccinia Immune Globulin Intravenous (VIGIV) to be used in the Strategic National Stockpile. VIGIV is the only therapeutic licensed by the US Food and Drug Administration (FDA) for the treatment of complications due to smallpox vaccination.

Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox

The development and ultimate approval of tecovirimat for the antiviral treatment of smallpox, a disease that has been eradicated from the world for nearly 40 years, required a unique regulatory approach based on the US Food and Drug Administration's Animal Rule.